Double Trigger in Patients With Low Proportion of Mature Oocytes
1 other identifier
interventional
66
1 country
1
Brief Summary
The aim of this randomized controlled trial is to determine whether co-administration of GnRH agonist and hCG for final oocyte maturation ( 40 and 34 h prior to oocyte retrieval , respectively) can increase the number of mature oocytes in patients with history of low proportion of mature oocytes in previous IVF cycle triggered by HCG.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2
Started May 2020
Shorter than P25 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 25, 2020
CompletedFirst Posted
Study publicly available on registry
May 29, 2020
CompletedStudy Start
First participant enrolled
May 30, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
February 2, 2021
CompletedMay 29, 2020
May 1, 2020
7 months
May 25, 2020
May 28, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of oocytes retrieved
First day after oocyte retrieval
Secondary Outcomes (1)
Clinical pregnancy rate
First 5 weeks after oocyte retrieval
Study Arms (2)
Double trigger
EXPERIMENTALGnRH-agonist and HCG are used to trigger ovulation
HCG
ACTIVE COMPARATORHCG is used to trigger ovulation
Interventions
Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Eligibility Criteria
You may qualify if:
- Patients with history of low proportion of mature oocytes in previous IVF attempt (triggered by HCG).
- Patients with 6 to 15 mature follicles on the day oocyte trigger in the current IVF-ET attempt
You may not qualify if:
- Endometriosis
- PCOS
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Riyadh Fertility and Reproductive Health center
Giza, Egypt
Related Publications (1)
Zilberberg E, Haas J, Dar S, Kedem A, Machtinger R, Orvieto R. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes. Gynecol Endocrinol. 2015 Feb;31(2):145-7. doi: 10.3109/09513590.2014.978850. Epub 2014 Nov 11.
PMID: 25385007BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Usama M Fouda, Prof.
Riyadh Fertility and Reproductive Health center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 25, 2020
First Posted
May 29, 2020
Study Start
May 30, 2020
Primary Completion
December 31, 2020
Study Completion
February 2, 2021
Last Updated
May 29, 2020
Record last verified: 2020-05